Flora H Duits1, Niels D Prins2, Afina W Lemstra2, Yolande A L Pijnenburg2, Femke H Bouwman2, Charlotte E Teunissen3, Philip Scheltens2, Wiesje M van der Flier4. 1. Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: f.duits@vumc.nl. 2. Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. 3. Department of Clinical Chemistry, Neurochemistry Laboratory and Biobank, VU University Medical Center, Amsterdam, The Netherlands. 4. Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: We aimed to assess the impact of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease on decision making and patient management in a tertiary memory clinic. METHODS: We included all patients, for 1 year, visiting the VUmc Alzheimer Center for cognitive screening. Neurologists completed questionnaires before and after CSF disclosure. We assessed the change of diagnosis, diagnostic confidence, and impact on patient management. RESULTS: A total of 438 patients (age 63 ± 8 years, 39% women) were included, of whom 351 (80%) underwent lumbar puncture. After the disclosure of CSF 23/351 diagnoses (7%) were changed. Diagnostic confidence increased from 84% to 89% (P < .001). There were consequences for management in 44/351 patients (13%) with CSF, and 13/87 patients (15%) because of unavailable CSF. There was no effect of age on these results. CONCLUSIONS: CSF biomarkers aid clinicians with decision making during diagnostic work-up of cognitive disorders. This study may be useful for developing guidelines for the implementation of CSF biomarkers in daily practice.
BACKGROUND: We aimed to assess the impact of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease on decision making and patient management in a tertiary memory clinic. METHODS: We included all patients, for 1 year, visiting the VUmc Alzheimer Center for cognitive screening. Neurologists completed questionnaires before and after CSF disclosure. We assessed the change of diagnosis, diagnostic confidence, and impact on patient management. RESULTS: A total of 438 patients (age 63 ± 8 years, 39% women) were included, of whom 351 (80%) underwent lumbar puncture. After the disclosure of CSF 23/351 diagnoses (7%) were changed. Diagnostic confidence increased from 84% to 89% (P < .001). There were consequences for management in 44/351 patients (13%) with CSF, and 13/87 patients (15%) because of unavailable CSF. There was no effect of age on these results. CONCLUSIONS: CSF biomarkers aid clinicians with decision making during diagnostic work-up of cognitive disorders. This study may be useful for developing guidelines for the implementation of CSF biomarkers in daily practice.
Authors: G Nicolas; C Charbonnier; D Wallon; O Quenez; C Bellenguez; B Grenier-Boley; S Rousseau; A-C Richard; A Rovelet-Lecrux; K Le Guennec; D Bacq; J-G Garnier; R Olaso; A Boland; V Meyer; J-F Deleuze; P Amouyel; H M Munter; G Bourque; M Lathrop; T Frebourg; R Redon; L Letenneur; J-F Dartigues; E Génin; J-C Lambert; D Hannequin; D Campion Journal: Mol Psychiatry Date: 2015-08-25 Impact factor: 15.992
Authors: Rik Ossenkoppele; Niklas Mattsson; Charlotte E Teunissen; Frederik Barkhof; Yolande Pijnenburg; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici Journal: Neurobiol Aging Date: 2015-04-25 Impact factor: 4.673
Authors: Valentina Garibotto; Nathalie L Albert; Henryk Barthel; Bart van Berckel; Ronald Boellaard; Matthias Brendel; Diego Cecchin; Ozgul Ekmekcioglu; Elsmarieke van de Giessen; Eric Guedj; Adriaan A Lammerstma; Franck Semah; Tatjana Traub-Weidinger; Donatienne Van Weehaeghe; Silvia Morbelli Journal: Eur J Nucl Med Mol Imaging Date: 2021-07-17 Impact factor: 9.236
Authors: Ingrid S van Maurik; Marissa D Zwan; Betty M Tijms; Femke H Bouwman; Charlotte E Teunissen; Philip Scheltens; Mike P Wattjes; Frederik Barkhof; Johannes Berkhof; Wiesje M van der Flier Journal: JAMA Neurol Date: 2017-12-01 Impact factor: 18.302
Authors: Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber Journal: World J Biol Psychiatry Date: 2017-10-27 Impact factor: 4.132
Authors: Júlia Faura; Alejandro Bustamante; Anna Penalba; Dolors Giralt; Alba Simats; Elena Martínez-Sáez; Daniel Alcolea; Juan Fortea; Alberto Lleó; Charlotte E Teunissen; Wiesje M van der Flier; Laura Ibañez; Oscar Harari; Carlos Cruchaga; Mar Hernández-Guillamón; Pilar Delgado; Joan Montaner Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472